DARE vs. HCWB, ACXP, CASI, NRXP, CARA, OCUP, GANX, AADI, NBRV, and IMRX
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include HCW Biologics (HCWB), Acurx Pharmaceuticals (ACXP), CASI Pharmaceuticals (CASI), NRx Pharmaceuticals (NRXP), Cara Therapeutics (CARA), Ocuphire Pharma (OCUP), Gain Therapeutics (GANX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), and Immuneering (IMRX). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Daré Bioscience presently has a consensus target price of $4.50, suggesting a potential upside of 1,002.67%. Given Daré Bioscience's higher probable upside, analysts clearly believe Daré Bioscience is more favorable than HCW Biologics.
Daré Bioscience has a net margin of 0.00% compared to HCW Biologics' net margin of -697.53%. HCW Biologics' return on equity of -146.76% beat Daré Bioscience's return on equity.
Daré Bioscience has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
In the previous week, Daré Bioscience had 2 more articles in the media than HCW Biologics. MarketBeat recorded 5 mentions for Daré Bioscience and 3 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.88 beat Daré Bioscience's score of 0.69 indicating that HCW Biologics is being referred to more favorably in the news media.
Daré Bioscience received 348 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 73.29% of users gave Daré Bioscience an outperform vote.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by insiders. Comparatively, 49.9% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
HCW Biologics has higher revenue and earnings than Daré Bioscience. HCW Biologics is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Daré Bioscience beats HCW Biologics on 9 of the 17 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
